Latest Research Report: Idecabtagene Vicleucel (ide-cel) Significantly Extends Progression-Free Survival in Triple-Class Exposed (TCE) Relapsed or Refractory Multiple Myeloma – Results from the KARMMA-3 Clinical Trial Academic Background and Research Question Patients with Multiple Myeloma (MM) often relapse after multiple lines of therapy, with pr...